Alto Neuroscience, Inc. (ANRO)
Form 4 sales, Form 144 notices and lockup dates Pharmaceutical Preparations, in Pharma.
- Latest sale
- $2.1M
- Nov 18 · Unusual
- Form 4 sales
- 2
- On record
- Form 144 notices
- 2
- Proposed sales
- Sold, last 30 days
- $2.1M
- 1 sale by 1 insider
- 0.2% of shares outstanding
- Sold, last 90 days
- $5.6M
- 2 sales by 2 insiders
- 0.5% of shares outstanding
- Next unlock
- None
- No lockup ahead
Lockups
None ahead
Every lockup on record has ended.
- IPO lockupAssumed dateJul 30, 2024 845 days ago
180 days from Feb 1, 2024. The prospectus also states 181 days and 90 days.
Sales by reason
0
Routine
0
Plan not stated
0
No plan
2
Unusual
Timeline
- Nov 18, 2026Unusual
Michael Conick Hanley Jr., CHIEF OPERATING OFFICER, sold 100% of their holdings
$2.1M75,000 shares at $27.61
- Nov 16, 2026Notice
Michael Conick Hanley Jr., CHIEF OPERATING OFFICER, filed a notice to sell 75,000 shares
$2.2M75,000 shares
- Sep 30, 2026Unusual
Nicholas Conrad Smith, PRESIDENT AND CFO, sold 84.9% of their holdings
$3.6M134,886 shares at $26.45
- Sep 29, 2026Notice
Nicholas Conrad Smith, PRESIDENT AND CFO, filed a notice to sell 134,886 shares
$3.6M134,886 shares
- Jul 31, 2024Lockup ends, assumed
Lockup assumed to end Jul 31, 2024
- Jul 30, 2024Lockup ends, assumed
Lockup assumed to end Jul 30, 2024
- May 1, 2024Lockup ends, assumed
Lockup assumed to end May 1, 2024
7 of 7
Every transaction
| Traded | Filed | Stock | Name | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 | Nov 18, 2026 | ANRO | Michael Conick Hanley Jr. | CHIEF OPERATING OFFICER | Sold | 75,000 | $27.61 | $2.1M | 0 | SEC |
| Nov 18, 2026 | Nov 18, 2026 | ANRO | Michael Conick Hanley Jr. | CHIEF OPERATING OFFICER | Exercised options | 75,000 | $2.35 | $176k | 2,896 | SEC |
| Oct 2, 2026 | Oct 5, 2026 | ANRO | Nicholas Conrad Smith | PRESIDENT AND CFO | Exercised or settledEmployee Stock Option (Right to Buy) | 55,000 | 57,405 | SEC | ||
| Oct 2, 2026 | Oct 5, 2026 | ANRO | Nicholas Conrad Smith | PRESIDENT AND CFO | Exercised options | 55,000 | $2.32 | $128k | 79,060 | SEC |
| Sep 30, 2026 | Oct 1, 2026 | ANRO | Nicholas Conrad Smith | PRESIDENT AND CFO | Sold | 134,886 | $26.45 | $3.6M | 24,060 | SEC |
| Sep 30, 2026 | Oct 1, 2026 | ANRO | Nicholas Conrad Smith | PRESIDENT AND CFO | Exercised or settledEmployee Stock Option (Right to Buy) | 134,886 | 121,818 | SEC | ||
| Sep 30, 2026 | Oct 1, 2026 | ANRO | Nicholas Conrad Smith | PRESIDENT AND CFO | Exercised options | 134,886 | $2.35 | $317k | 48,116 | SEC |
| May 27, 2026 | May 29, 2026 | ANRO | Andrew Craig Miller | Director | AwardedStock Option (right to buy) | 26,000 | 26,000 | SEC | ||
| May 14, 2026 | May 15, 2026 | ANRO | Amit Etkin | PRESIDENT AND CEO | Gift | 400,000 | 833,949 | SEC | ||
| May 12, 2026 | May 14, 2026 | ANRO | Husseini Manji | Director | AwardedStock Option (right to buy) | 10,958 | 10,958 | SEC | ||
| May 12, 2026 | May 14, 2026 | ANRO | Gwill York | Director | AwardedStock Option (right to buy) | 10,958 | 10,958 | SEC | ||
| May 12, 2026 | May 14, 2026 | ANRO | Christopher Nixon Cox | Director | AwardedStock Option (right to buy) | 10,958 | 10,958 | SEC | ||
| May 12, 2026 | May 14, 2026 | ANRO | Ramiro Sanchez | Director | AwardedStock Option (right to buy) | 10,958 | 10,958 | SEC | ||
| May 12, 2026 | May 14, 2026 | ANRO | Andrew Dreyfus | Director | AwardedStock Option (right to buy) | 10,958 | 10,958 | SEC | ||
| Mar 1, 2026 | Mar 3, 2026 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | Withheld for tax | 2,806 | $19.69 | $55k | 24,060 | SEC |
| Mar 1, 2026 | Mar 3, 2026 | ANRO | Amit Etkin | PRESIDENT AND CEO | Withheld for tax | 6,227 | $19.69 | $123k | 1.2M | SEC |
| Feb 11, 2026 | Feb 13, 2026 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | AwardedEmployee Stock Option (Right to Buy) | 200,000 | 200,000 | SEC | ||
| Feb 11, 2026 | Feb 13, 2026 | ANRO | Adam Savitz | CHIEF MEDICAL OFFICER | AwardedEmployee Stock Option (Right to Buy) | 124,000 | 124,000 | SEC | ||
| Feb 11, 2026 | Feb 13, 2026 | ANRO | Amit Etkin | PRESIDENT AND CEO | AwardedEmployee Stock Option (Right to Buy) | 306,000 | 306,000 | SEC | ||
| Feb 11, 2026 | Feb 13, 2026 | ANRO | Michael Conick Hanley Jr. | CHIEF OPERATING OFFICER | AwardedEmployee Stock Option (Right to Buy) | 131,000 | 131,000 | SEC | ||
| Jan 2, 2026 | Jan 6, 2026 | ANRO | Husseini Manji | Director | AwardedEmployee Stock Option (right to buy) | 4,228 | $11.82 | $50k | 4,228 | SEC |
| Jan 2, 2026 | Jan 6, 2026 | ANRO | Gwill York | Director | AwardedStock Option (right to buy) | 5,243 | $11.82 | $62k | 5,243 | SEC |
| Jan 2, 2026 | Jan 6, 2026 | ANRO | Christopher Nixon Cox | Director | AwardedStock Option (right to buy) | 7,189 | $11.82 | $85k | 7,189 | SEC |
| Jan 2, 2026 | Jan 6, 2026 | ANRO | Ramiro Sanchez | Director | AwardedStock Option (right to buy) | 3,806 | $11.82 | $45k | 3,806 | SEC |
| Aug 12, 2025 | Aug 14, 2025 | ANRO | Ramiro Sanchez | Director | AwardedStock Option (right to buy) | 34,502 | $0.25 | $9k | 3,928 | SEC |
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Michael Conick Hanley Jr. | CHIEF OPERATING OFFICER | Returned to the companyEmployee Stock Option (Right to Buy) | 321,000 | 0 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Michael Conick Hanley Jr. | CHIEF OPERATING OFFICER | AwardedEmployee Stock Option (Right to Buy) | 321,000 | 125,000 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Adam Savitz | CHIEF MEDICAL OFFICER | Returned to the companyEmployee Stock Option (Right to Buy) | 328,134 | 0 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Adam Savitz | CHIEF MEDICAL OFFICER | AwardedEmployee Stock Option (Right to Buy) | 328,134 | 76,000 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Amit Etkin | PRESIDENT AND CEO | Returned to the companyEmployee Stock Option (Right to Buy) | 719,910 | 0 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Amit Etkin | PRESIDENT AND CEO | AwardedEmployee Stock Option (Right to Buy) | 719,910 | 215,000 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | Returned to the companyEmployee Stock Option (Right to Buy) | 506,124 | 0 | SEC | ||
| Jul 3, 2025 | Jul 8, 2025 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | AwardedEmployee Stock Option (Right to Buy) | 506,124 | 135,000 | SEC | ||
| May 13, 2025 | May 15, 2025 | ANRO | Husseini Manji | Director | AwardedStock Option (right to buy) | 15,287 | 15,287 | SEC | ||
| May 13, 2025 | May 15, 2025 | ANRO | Christopher Nixon Cox | Director | AwardedStock Option (right to buy) | 15,287 | 15,287 | SEC | ||
| May 13, 2025 | May 15, 2025 | ANRO | Andrew Dreyfus | Director | AwardedStock Option (right to buy) | 15,287 | 15,287 | SEC | ||
| May 13, 2025 | May 15, 2025 | ANRO | Gwill York | Director | AwardedStock Option (right to buy) | 15,287 | 15,287 | SEC | ||
| Feb 5, 2025 | Feb 7, 2025 | ANRO | Michael Conick Hanley Jr. | CHIEF OPERATING OFFICER | AwardedEmployee Stock Option (Right to Buy) | 125,000 | 125,000 | SEC | ||
| Feb 5, 2025 | Feb 7, 2025 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | AwardedEmployee Stock Option (Right to Buy) | 135,000 | 135,000 | SEC | ||
| Feb 5, 2025 | Feb 7, 2025 | ANRO | Adam Savitz | CHIEF MEDICAL OFFICER | AwardedEmployee Stock Option (Right to Buy) | 76,000 | 76,000 | SEC | ||
| Feb 5, 2025 | Feb 7, 2025 | ANRO | Amit Etkin | PRESIDENT AND CEO | AwardedEmployee Stock Option (Right to Buy) | 215,000 | 215,000 | SEC | ||
| Jan 2, 2025 | Jan 6, 2025 | ANRO | Gwill York | Director | AwardedStock Option (right to buy) | 19,558 | $3.17 | $62k | 19,558 | SEC |
| Jan 2, 2025 | Jan 6, 2025 | ANRO | Husseini Manji | Director | AwardedStock Option (right to buy) | 14,195 | $3.17 | $45k | 14,195 | SEC |
| Jan 2, 2025 | Jan 6, 2025 | ANRO | Christopher Nixon Cox | Director | AwardedStock Option (right to buy) | 25,236 | $3.17 | $80k | 25,236 | SEC |
| Jul 10, 2024 | Jul 11, 2024 | ANRO | Adam Savitz | CHIEF MEDICAL OFFICER | Bought | 15,000 | $12.72 | $191k | 39,851 | SEC |
| May 20, 2024 | May 22, 2024 | ANRO | Michael Conick Hanley Jr. | Chief Operating Officer | AwardedEmployee Stock Option (right to buy) | 188,000 | 188,000 | SEC | ||
| Mar 28, 2024 | Apr 1, 2024 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | Bought | 6,150 | $16.36 | $101k | 26,866 | SEC |
| Mar 8, 2024 | Mar 12, 2024 | ANRO | Maha Radhakrishnan | Director | AwardedStock Option (right to buy) | 32,164 | $0.50 | $16k | 1,590 | SEC |
| Mar 1, 2024 | Mar 5, 2024 | ANRO | Adam Savitz | CHIEF MEDICAL OFFICER | AwardedEmployee Stock Option (Right to Buy) | 73,000 | 73,000 | SEC | ||
| Mar 1, 2024 | Mar 5, 2024 | ANRO | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | AwardedEmployee Stock Option (Right to Buy) | 90,000 | 90,000 | SEC |
Page 1
Sales, notices and lockups (7)
Export watchlist as CSV| Source | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 | Nov 18, 2026 | Michael Conick Hanley Jr. | ANRO | CHIEF OPERATING OFFICER | Form 4 sale | 75,000 | $2.1M | 100.0% | Unusual | SEC |
| Nov 16, 2026 | Nov 16, 2026 | Michael Conick Hanley Jr. | ANRO | CHIEF OPERATING OFFICER | Form 144 notice | 75,000 | $2.2M | Notice | SEC | |
| Sep 30, 2026 | Oct 1, 2026 | Nicholas Conrad Smith | ANRO | PRESIDENT AND CFO | Form 4 sale | 134,886 | $3.6M | 84.9% | Unusual | SEC |
| Sep 29, 2026 | Sep 29, 2026 | Nicholas Conrad Smith | ANRO | PRESIDENT AND CFO | Form 144 notice | 134,886 | $3.6M | Notice | SEC | |
| Jul 31, 2024 | Feb 5, 2024 | All locked holders | ANRO | Lockup expiry | Lockup ends, assumed | SEC | ||||
| Jul 30, 2024 | Feb 5, 2024 | All locked holders | ANRO | Lockup expiry | Lockup ends, assumed | SEC | ||||
| May 1, 2024 | Feb 5, 2024 | All locked holders | ANRO | Lockup expiry | Lockup ends, assumed | SEC |